The obese population that we receive for FibroScan® examinations has increased substantially in recent years. CAP™ has become essential to our prescribers to precisely monitor patient’s steatosis.
The obese population that we receive for FibroScan® examinations has increased substantially in recent years. CAP™ has become essential to our prescribers to precisely monitor patient’s steatosis.
Subscribe to our mailing list to receive updates on articles, white papers and educational webinars for the management and treatment of chronic liver disease.